People

Intranasal epinephrine developer Bryn Pharma announced that former Aerami Therapeutics Chief Operating Officer Joshua Ziel has joined the company as CEO, succeeding Sandy Loreaux. Prior to joining Aerami in 2022, Ziel held management positions at… Read more . . .

Inhaled drug developer Transpire Bio has announced the hires of Timothy Lutz as VP of Manufacturing and Operations; Stuart Loesch as Chief Commercial Officer; and Todd Sunstrom as Head of Quality Assurance. The company recently… Read more . . .

UK-based Synairgen, which is developing SNG001 inhaled interferon-beta-1a, announced that former Chiesi Global Head of Drug Development Mark Parry-Billings will succeed Simon Shaw as Chairman of the Board. Shaw will retire in October 2024. Prior to… Read more . . .

Nasal drug developer Leyden Laboratories announced that former Moderna vaccine development executive Jintanat Ananworanich has joined the company as Chief Medical Officer. Ananworanich was most recently Executive Director of clinical development at Moderna, and her… Read more . . .

Nocion Therapeutics, whose taplucainium (NTX-1175) DPI is in Phase 2 development for the treatment of chronic cough, has announced the appointments of two former Bellus Health executives, naming Catherine Bonuccelli to the scientific advisory board… Read more . . .

Cardiff Scintigraphics, has announced the appointment of OINDP expert John Pritchard as the company’s Chairman of the Board, succeeding David Owen. The news comes soon after Cardiff Scintigraphics, the parent company of inhalation CRO i2c… Read more . . .

Disposable dry powder inhaler developer 1nhaler has announced the appointment of former AstraZeneca VP Jane Gaddum as Board Chair and non-executive director and former GSK VP Gordon Muirhead as a non-executive director. Gaddum was AstraZeneca… Read more . . .

UK-based Enterprise Therapeutics, which is developing inhaled ENaC blockers for the treatment of cystic fibrosis and other respiratory conditions, has named former Insmed Executive VP of Development and Chief Medical Officer Renu Gupta as the… Read more . . .

Cardiff Scintigraphics, the parent company of inhalation CRO i2c Pharma Services, has named former OBG Pharmaceuticals Chief Scientific Officer Andrew Brown as CEO, succeeding Glyn Taylor, who will continue part time as Chief Scientific Officer.… Read more . . .